News | June 10, 2025
Glenmark Pharmaceuticals to launch DCGI-approved BRUKINSA in India for treatment of hematological malignancies
Globally, BRUKINSA is approved in more than 70 countries
Globally, BRUKINSA is approved in more than 70 countries
The market size of Aspart in India is currently estimated over Rs. 260 crore with only 2 players
DCGI has also granted permission to manufacture and market FDF of Cefepime and Enmetazobactam as a dry powder injectable
The approval allows treatment of heart failure patients irrespective of the ejection fraction based on new trial DELIVER conducted by AstraZeneca
Themis will market this drug with the brand name REMITHEM.
Lynparza is the first and only approved PARPi targeting BRCA-mutated HER2-negative high-risk early breast cancer
It is a two dose vaccine to be administered intramuscularly at 28 days apart
Low-dose atropine has emerged as an effective approach to slow the progression of myopia in children
The approval comes soon after Corbevax was given the nod for 12-15-year group
Covaxin was earlier approved for children 12-18 years of age
Subscribe To Our Newsletter & Stay Updated
